Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer

ALEXANDER PHILIPOVSKIY, ALELI CAMPBELL, ROSALINDA HEYDARIAN, BRENDA CASTILLO, ALOK K. DWIVEDI, RICHARD MCCALLUM, RENATO AGUILERA, SUMIT GAUR and ZEINA NAHLEH
Anticancer Research February 2020, 40 (2) 857-864; DOI: https://doi.org/10.21873/anticanres.14018
ALEXANDER PHILIPOVSKIY
1Division of Hematology-Oncology, Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alexander.philipovskiy@ttuhsc.edu
ALELI CAMPBELL
2Department of Metallurgical, Materials and Biomedical Engineering, University of Texas, El Paso, TX, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROSALINDA HEYDARIAN
1Division of Hematology-Oncology, Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BRENDA CASTILLO
1Division of Hematology-Oncology, Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALOK K. DWIVEDI
3Division of Biostatistics & Epidemiology, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RICHARD MCCALLUM
4Division of Gastroenterology, Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RENATO AGUILERA
5Department of Biological Sciences, University of Texas, El Paso, TX, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUMIT GAUR
1Division of Hematology-Oncology, Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZEINA NAHLEH
6Maroone Cancer Center Department of Hematology-Oncology, Cleveland Clinic Florida, Weston, FL, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: The purpose of this study was to determine the level of adherence to adjuvant aromatase inhibitor (AI) therapy and factors associated with non-adherence among Hispanic/Latino women with hormonal receptor-positive breast cancer (BC) treated at an academic center at the American–Mexican border city of El Paso, TX. Patients and Methods: Institutional Review Board approval was obtained in this cross-sectional study using the validated Morisky Medication Adherence Scale to assess patient adherence to AI therapy. Patients diagnosed with stage I-III hormonal receptor-positive, human epidermal growth factor receptor 2-negative BC who were on adjuvant AIs therapy were recruited from the Texas Tech University Health Sciences Center El Paso breast clinic. Results: Between September 2017 and August 2018, 122 consecutive patients were enrolled; 119 were analyzed, three were lost to follow up. The mean age was 61.6±9.4 years, and 109 (91.6%) self-identified as Hispanic/Latino. A total of 58% reported an annual income of $15,000 or less. Overall, 40.3% had completed eighth grade or less education, 31.9% high school, and 12% had obtained a technical degree. The majority of patients (56%) had either a medium (45%) or a low level of adherence (11%). High adherence was noted in 44% of participants. Seven (5.6%) patients scored 2 or below on a 4–point scale for intentional adherence, and 18 (13.5%) scored 2 or below on a 4-point scale for unintentional adherence. Conclusion: These data suggest that the majority of Hispanic/Latino women with breast cancer have medium or low levels of adherence to therapy with AIs. Factors associated with medium and low adherence were unintentional (forgetfulness), but also included intentional factors, such as avoidance of adverse effects and delays with obtaining refills (cost-related nonadherence).

  • Adjuvant aromatase inhibitor
  • breast cancer
  • postmenopausal
  • adherence

Breast cancer (BC) is the second leading cause of cancer death after lung cancer in the United States (1). In 2018, the American Cancer Association estimated that there were 252,700 new cases of BC in the United States and 41,000 deaths from the disease (1). It is the major type of cancer among Hispanic/Latino women in the United States, with approximately 20,000 new cases and 3,000 deaths per year(2). From 2003 to 2018, the incidence rate of BC remained stable in both Hispanic and non-Hispanic White women (2). The use of screening mammography and advances in treatment modalities including the use of adjuvant endocrine therapy have contributed to the reduction of mortality from BC in the United States by approximately 24% since 1990 (3). Multiple studies have shown substantial benefits from adjuvant endocrine therapy in improving progression-free and overall survival (4-7). For almost two decades, adjuvant endocrine therapy with an aromatase inhibitor (AI) has remained a gold-standard for patients with hormonal receptor-positive BC. In 2003, the first results of ATAC (arimidex, tamoxifen, alone or in combination) phase III clinical trial demonstrated a statistically significant advantage in disease-free survival among postmenopausal women initially taking anastrozole compared with tamoxifen as adjuvant therapy for hormonal receptor-positive local or locally advanced disease (6). Subsequent large clinical trials have confirmed the role of AI therapy in the management of postmenopausal women with BC and demonstrated a significant reduction of 30% in BC recurrence (5, 8-11). Despite the efficacy of AIs, it has been reported that the self-discontinuation rate is approaching 10% per year nationwide and that only 40-60% of women with BC complete 5 years of adjuvant endocrine therapy (12). There are multiple factors associated with self-discontinuation and non-adherence: cultural, limited insurance, lack of follow-up information, severity of adverse effects, older age or very young age, forgetfulness, trust in the physician and understanding of treatment recommendation. Early discontinuation can translate into a higher likelihood of relapse and shorter survival. A recent study of patients who were non-adherent (defined as omitting endocrine therapy for 180 days) showed an adjusted odds ratio for cancer recurrence of 2.88 compared to patients who did not adhere to therapy (13). Some studies have suggested a higher recurrence rate of BC among Hispanic/Latino women which might be at least partially related to early discontinuation or poor adherence rate to AI therapy (14-17). There is a paucity of studies assessing the adherence or discontinuation rate among Hispanic/Latino women and no prospective trial, to our knowledge, has addressed adherence to AI therapy among the Hispanic/Latino population.

The aim of this study was to assess the adherence rate to adjuvant endocrine therapy in patients seen at the Breast Care Center/Texas Tech University Health Sciences Center El Paso with estrogen receptor (ER)/progesterone receptor (PR)-positive BC living in the border City of El-Paso, Texas and to identify potential modifiable factors associated with AI non-adherence.

Patients and Methods

Patient population. This prospective (cross-sectional) study was approved by the Institutional Review Board of the Texas Tech University Health Sciences Center (TTUHSC), El Paso. The study population consisted predominantly from Hispanic/Latino (91.6%) women living in the border city of El Paso, Texas and treated at TTUHSC, an academic medical center. To be eligible, women had to be diagnosed with stage I-III (with no evidence of metastatic disease, M0) histologically confirmed hormonal receptor-positive (ER/PR) invasive BC and be receiving adjuvant AI therapy (anastrozole, letrozole, or exemestane) for at least 1 month. Participants were to have completed all recommended local therapies (surgery, radiation if appropriate) and have recovered from all side-effects of chemotherapy, surgery, and radiation therapy. We excluded all male patients, patients with metastatic BC and premenopausal women who had not undergone menopause either surgically by oophorectomy or by hormonal ovarian ablation.

Patients were required to be able to complete a self-reported demographic questionnaire and the validated Morisky Medication Adherence Scale questionnaire (MMAS-8), in either English or Spanish [detailed MMAS-8 questionnaires can be found elsewhere (18, 19). Self-reported medication adherence was measured by the MMAS-8 (18, 19). The MMAS-8 scale consists of eight items, of which summation yields a maximum of 8 points. Level of adherence to AI therapy was categorized as high, medium, and low (18, 19).

The purpose of this study was to estimate the level of adherence to adjuvant AI therapy and the main factors associated with non-adherence among Hispanic/Latino women living in the border City of El-Paso, Texas, USA.

Pathological assessment. Pathological diagnosis, ER/PR status, and human epidermal growth factor receptor 2 (HER2)/neu status were determined by core biopsy during the initial evaluation before surgery. Standard immunohistochemical staining was used to determine hormonal receptor status. All tumors with more than 1% stained cells were considered to have a positive hormonal receptor status.

Statistical analysis. It has been shown in previous studies that the non-adherence rate to AIs range. From 20% to 75% (15, 20-27). Assuming a non-adherence rate of 30% in our population, a sample size of 89 was sufficient to produce a two-sided 95% confidence interval (CI) with a width of 20% using a Z-test. Furthermore, this sample size was more than sufficient to evaluate at least five predictors for non-adherence using multiple logistic regression analysis with more than 80% power. The sample size estimation was carried out using PASS 14 (NCSS, LLC., Kaysville, UT, USA). The medium and low adherence rate to AI therapy (<8 on MMAS-8) was estimated along with 95% CI using a Z-test. Clinical and demographic cofactors were described using appropriate summary measures such as the mean or median, and standard deviation for quantitative data, while the frequency and proportion were used for categorical data. Furthermore, non-normal data was described using median and interquartile range. A logarithmic transformation was made to induce normality for non-Gaussian data. The frequency and cumulative frequency distribution of adherence rate was summarized. Chi-squared test and one-way ANOVA were used to compare the characteristics between non-adherent and adherent groups. The unadjusted and adjusted predictors of adherence levels were assessed using linear regression models and log Poisson regression models and reported as regression coefficients and odds ratio, 95% CI and p-value. p-Values of less than 5% were considered statistically significant. All the statistical analyses were conducted using STATA 14 (StataCorp LLC, College Station, TX USA) SAS 9.4 (SAS, Cary, NC, USA) and SPSS Statistics 25 (IBM, Armonk, NY, USA).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Clinical characteristics of the entire cohort, and by adherence levels (n=119).

Results

Between 2017 and 2018, a total of 122 patients were enrolled. Of these, 119 consecutive postmenopausal women with hormonal receptor-positive BC were included in this analysis. Table I shows the summary clinical profile of patients. Of these, 85 (71.4%) patients were born in Mexico, 31 (26.1%) were from the USA, and the remaining three (2.5%) were classified as being from other nations (Philippines, Germany, and Nicaragua). The mean age of the patients was 61.6 ± 9.4 years. A total of 109 (91.6%) identified themselves as Hispanic/Latino, and 10 (8.4%) as other [Caucasian, African American (AA), Asian and unknown]. Overall, 58% (n=69) of patients were of low socioeconomic status, 40% (n=48) had attended elementary or middle school (≤8th grade), 32% (n=32) had obtained a high school diploma or General Educational Development certificate), and 28% (n=33) had pursued a higher education.

The average MMAS-8 score was estimated as 7±1.2 (range=1-8). Overall, low/medium adherence rate of AI was estimated as 56% (95% CI=47-65%). Patients were divided into three groups according to adherence level: High, medium, and low, in an attempt to determine factors associated with inferior (medium and low) adherence. The medium and high adherence categories had higher numbers of participants, whereas the number in the low adherence group was smaller. We identified that a medium level and high level of adherence to AI was quite common among our patients, with 11% reporting a low level of adherence, 45% (n=54) reporting a medium adherence, and 44% reporting a high level of adherence. The intentional and unintentional subcategories of the adherence MMAS-8 model were also evaluated. The rate of intentional low/medium adherence was 26% (n=31), while the unintentional rate was 51% (n=61). In total, 25 patients had low adherence for both unintentional and intentional reasons. The answers identifying reasons for not taking their cancer therapy included: side-effects, forgetfulness, too expensive, and other reasons; forgetfulness was the highest (63%, n=75), delays in refills (5%, n=6), AEs (5%, n=6) and lack of insurance (3%, n=4). Some of the reasons listed for intentional low adherence were withholding all medications due to other health procedures, lack of insurance and tiredness. Reasons for unintentional low adherence were forgetfulness, and lack of insurance.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Unadjusted association between cofactors and high adherence level compared to low/medium adherence level.

Table I also shows clinical characteristics of patients according to adherence level. Among all considered cofactors, the distribution of age of patients, duration of AI treatment, and parity status were found to be different across different adherence levels. Younger age, greater than 5 years of duration of AI, and multiparity seem to be associated with a low or medium adherence level.

A summary of overall adherence with respect to variables measured and age is provided in Table II using a one-way ANOVA to evaluate adherence based on two age groups (<60 and ≥60 years); there was a statistically significant mean age difference of 0.5 (p=0.04) between these groups. Table II shows the unadjusted association of cofactors with a high adherence level compared to combined low or medium adherence. This analysis further suggested that older age, less duration of AI treatment, and nulliparity tended to be associated with a high adherence level. The actual mean age of the low adherence group was lower than that of the other two groups (medium and high adherence). The difference was not statistically significant; however, it is worth noting that the mean age for the low adherence group was 57 years, while that for the high adherence group was 62 years. Results from a multinomial logistic regression analysis indicate that the age group below 60 years of age was 4.25 times more likely to exhibit low adherence to AI therapy compared to the older group (≥60 years) (p=0.03). Furthermore, the <60 years age group was also 1.4 times more likely to have medium adherence compared to the older group (p=0.357).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Adjusted associations of factors with high adherence level.

In the adjusted analyses, only older age and a nulliparous status were more likely to be associated with a high (Table III) as well as medium (Table IV) adherence level after adjusting for education status.

Other demographic factors such as marital status, education and income level were also evaluated in Table III. No significant associations were observed, all ORs were <1 (results not shown).

BC stage was not associated with medium and high adherence which was very similar among the three BC stages, whereas for low adherence, the relatively smaller group size across all cancer stages preclude any conclusion.

Discussion

This cross-sectional study suggests a high non-adherence rate to adjuvant AI and indicates that the majority of women surveyed (56%) reported medium or low adherence to this vital treatment. Non-adherence to adjuvant endocrine therapy is a complex and multifactorial problem that can substantially alter the outcome of medical treatment and has been associated with an increase in BC relapse, additional physician visits, higher hospitalization rates, and shorter survival (21, 28-30). Identifying modifiable causes of non-adherence is an important priority and needs to be promptly addressed (11, 31). Our findings indicate that the majority of the participants surveyed had medium or low compliance with adjuvant endocrine therapy, which is a particularly concern in the current era of trends towards minimally effective treatments, and more reliance on adjuvant endocrine therapy as opposed to previously overtreating patients with adjuvant chemotherapy. This was the result of the introduction of genomic analyses into standard care for early-stage ER/PR-positive and HER2-neu-negative BC, reducing the use of chemotherapy significantly (32). Therefore, adherence to adjuvant endocrine therapy is now ever more important for patients with BC who may rely on this treatment as the sole systemic treatment modality due to the recent evolution of modern care.

In this study we identified three main reasons for non-adherence: Forgetfulness, adverse events, and delays with getting refills (cost-related non-adherence). While forgetfulness is a quite common form of unintentional non-adherence, based on retrospective and prospective memory failure (33), we feel that this is a potentially modifiable factor, especially in view of high degree of forgetfulness in elderly patients (>50% of our patient population). Interventions to address this problem may include implementing simple measures such as cueing, chaining (associating new and established behaviors), use of social support and ancillary clinical services (family members, nurses, pharmacists), and electronic monitoring devices. For patients with a cellular device, the option to add a reminder in their calendar could be recommended by their care specialists. Physicians can help by simplifying seniors' complex medical regimens (using once-daily dosing) and discontinuing unnecessary medications. Assessment of the usefulness of a text message reminder to patients to continue their endocrine therapy is currently being studied in a randomized controlled trial (SWOG 1105/NCT01515800). Some studies have suggested more frequent follow-up visits and follow-up with specialists rather than general practitioners might have a positive impact on adherence (27). An interesting observation in our study was that patient parity was positively associated with adherence. Multiparous women were more likely to be highly adherent compared to nulliparous ones. At this point, we do not have explanations for this finding.

Reasons for non-adherence have been previously studied (17, 34-37). Multiple studies have evaluated factors correlated with non-adherence to endocrine adjuvant therapy (28, 34). Most commonly reported factors associated with non-adherence were sociodemographic factors (patient age, race and ethnicity), treatment-related factors (type of breast surgery, side-effects of chemotherapy), cost-related factors - low income, defined by Medicaid as adults with incomes up to 138% the Federal Poverty Level of $29,435 per year for a family of three and $17,236 per year for an individual in 2019, as well as beliefs about the benefits and risks of endocrine therapy (20, 28, 34, 37, 38).

There are limited data in modern literature addressing adherence to adjuvant endocrine therapy among women of racial/ethnical minority groups. In one retrospective, cross-sectional study, Gerber et al. analyzed 450 Medicare cases of patients on adjuvant endocrine therapy. They identified a statistically significant difference in adherence to endocrine therapy between African Americans (AA) and Non-Hispanic White women. More AAs reported not following their physician's instruction on how to take medications and reported early self-discontinuation (16). Another study demonstrated poor level of adherence in both AA and Hispanic/Latino women. AA and Hispanic/Latino women were more likely than non-Hispanic Whites to report cost-related non-adherence (35.1%, 36.5% and 26.7%, respectively, p<0.001) (17). However, these studies were somewhat inconsistent, and the methodology used to gather data was not standardized, which can lead to incomplete conclusions. Our data showed slightly lower non-adherence rates compared to national and international published nonadherence data (22, 23, 25, 26, 34, 36, 39). The strengths of our analysis include the licensing and utilization of the validated 8-item MMAS-8 adherence questionnaire as described previously (18, 19, 40, 41). In addition, the average duration of adjuvant endocrine therapy was 4.3 years, which allowed for assessment of long-term adherence to therapy. Previous studies using self-reported adherence to tamoxifen or AI therapy have found that approximately 15% to 35% of women discontinue their therapy prematurely at varying lengths of follow-up (26, 34, 39). A large retrospective study in Ireland using insurance claims-based methodology reported that 22% of women had discontinued tamoxifen by the end of the first year of adjuvant therapy, and by 3.5 years, 35% had discontinued therapy (28). Hershman et al. retrospectively analyzed adherence of 8,769 patients with early stage BC to adjuvant endocrine therapy (tamoxifen and AI). At 4.5 years of treatment, 32% of patient had self-discontinued adjuvant endocrine therapy. Additionally, women younger than 40 years of age had the highest rate of discontinuation (hazard ratio=1.51:95% CI=1.23-1.85) (15).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Adjusted associations of factors with high and medium adherence levels.

Our study had several limitations. The cross-sectional design did not allow for the assessment of changes in adherence over time. However, it provided what we believe to be a good representation of adherence rates in a large cohort of Hispanic/Latino patients (91.6%), as well as information regarding some potential factors which affect adherence in this minority population which could be useful to improve adherence rates in this population. The study population was possibly limited by selection bias as patients with the poorest adherence to therapy may not attend their clinical follow-up, and therefore may not have been captured by this study. Moreover, patient self-reported adherence rates might overestimate real-world adherence when compared to actual prescription fill rates, as shown in some studies (16, 17, 23).

In conclusion, these data suggest a low level of adherence to adjuvant endocrine therapy in the Hispanic-Latino women with BC. Factors associated with non-adherence included forgetfulness, adverse effects, and delay with obtaining refills due to cost. Appropriate education and frequent assessment of adherence and management of side-effects, combined with close monitoring with BC specialists, might help improve endocrine therapy adherence in all women with early-stage BC, including Hispanic/Latino women and other minorities.

Acknowledgements

The Authors would like to acknowledge Sean Connery, Christopher Dodo, Krysta Lin and Zeinab Abdularhman for their efforts in article preparation. We thank Professor Donald E. Morisky, Department of Community Health Sciences, UCLA Fielding School of Public Health, Los Angeles, United States, for granting us the use of the copyrighted MMAS-8. Professor Morisky has worked his entire career in developing the very important instrument for medication-taking behavior measure. Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, 14725 NE 20th St Bellevue, WA 98007, USA; dmoriskiy{at}gmail.com.

Footnotes

  • Authors' Contributions

    AP conceived the study and prepared the draft of the article. AC participated in drafting the article and study conception. RH participated in drafting the article and approved the article. AKD performed statistical analysis and participated in drafting the article. RM participated in drafting the article and approved the article. RA participated in drafting and final revision of the article and approved the article. SG participated in the design of the study and approved the article. NZ conceived the study and approved the article.

  • This article is freely accessible online.

  • Funding

    Texas Tech University Medical Sciences Center. Department of Internal Medicine. Seed Founding program 2017-2018.

  • Conflicts of Interest

    Alexander Philipovskiy declares that he has no conflict of interest. Aleli Campbell declares that she has no conflict of interest. Dwivedi Kumar Alok declares that he has no conflict of interest. Brenda Castillo declares that she has no conflict of interest. Heydarian Rosalinda. declares that she has no conflict of interest. Richard McCallum declares that he has no conflict of interest in medical oncology. Renato Aguilera declares that he has no conflict of interest in medical oncology. Sumit Guar declares that he has no conflict of interest. Nahleh Zeina declares that she has no conflict of interest.

  • Received December 5, 2019.
  • Revision received December 29, 2019.
  • Accepted January 13, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    : Cancer statistics, 2018. CA Cancer J Clin 68(1): 7-30, 2018. PMID: 29313949. DOI: 10.3322/caac.21442
    OpenUrlCrossRefPubMed
  2. ↵
    1. Miller KD,
    2. Goding Sauer A,
    3. Ortiz AP,
    4. Fedewa SA,
    5. Pinheiro PS,
    6. Tortolero-Luna G,
    7. Martinez-Tyson D,
    8. Jemal A,
    9. Siegel RL
    : Cancer statistics for hispanics/latinos, 2018. CA Cancer J Clin, 2018. PMID: 30285281. DOI: 10.3322/caac.21494
  3. ↵
    1. Parkin DM,
    2. Bray FI,
    3. Devesa SS
    : Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8): S4-66, 2001. PMID: 11602373.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Mouridsen HT,
    2. Robert NJ
    : The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 41(12): 1678-1689, 2005. PMID: 16098456. DOI: 10.1016/j.ejca.2004.10.020
    OpenUrlCrossRefPubMed
  5. ↵
    1. Crivellari D,
    2. Sun Z,
    3. Coates AS,
    4. Price KN,
    5. Thurlimann B,
    6. Mouridsen H,
    7. Mauriac L,
    8. Forbes JF,
    9. Paridaens RJ,
    10. Castiglione-Gertsch M,
    11. Gelber RD,
    12. Colleoni M,
    13. Lang I,
    14. Del Mastro L,
    15. Gladieff L,
    16. Rabaglio M,
    17. Smith IE,
    18. Chirgwin JH,
    19. Goldhirsch A
    : Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The big 1-98 trial. J Clin Oncol 26(12): 1972-1979, 2008. PMID: 18332471. DOI: 10.1200/JCO.2007.14.0459
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Eastell R,
    2. Adams JE,
    3. Coleman RE,
    4. Howell A,
    5. Hannon RA,
    6. Cuzick J,
    7. Mackey JR,
    8. Beckmann MW,
    9. Clack G
    : Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26(7): 1051-1057, 2008. PMID: 18309940. DOI: 10.1200/JCO.2007.11.0726
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Goss PE,
    2. Ingle JN,
    3. Pritchard KI,
    4. Ellis MJ,
    5. Sledge GW,
    6. Budd GT,
    7. Rabaglio M,
    8. Ansari RH,
    9. Johnson DB,
    10. Tozer R,
    11. D'Souza DP,
    12. Chalchal H,
    13. Spadafora S,
    14. Stearns V,
    15. Perez EA,
    16. Liedke PE,
    17. Lang I,
    18. Elliott C,
    19. Gelmon KA,
    20. Chapman JA,
    21. Shepherd LE
    : Exemestane versus anastrozole in postmenopausal women with early breast cancer: Ncic ctg ma.27--a randomized controlled phase iii trial. J Clin Oncol 31(11): 1398-1404, 2013. PMID: 23358971. DOI: 10.1200/JCO.2012.44.7805
    OpenUrlPubMed
  8. ↵
    1. Goss PE,
    2. Ingle JN,
    3. Martino S,
    4. Robert NJ,
    5. Muss HB,
    6. Piccart MJ,
    7. Castiglione M,
    8. Tu D,
    9. Shepherd LE,
    10. Pritchard KI,
    11. Livingston RB,
    12. Davidson NE,
    13. Norton L,
    14. Perez EA,
    15. Abrams JS,
    16. Therasse P,
    17. Palmer MJ,
    18. Pater JL
    : A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19): 1793-1802, 2003. PMID: 14551341. DOI: 10.1056/NEJMoa032312
    OpenUrlCrossRefPubMed
    1. Coombes RC,
    2. Hall E,
    3. Gibson LJ,
    4. Paridaens R,
    5. Jassem J,
    6. Delozier T,
    7. Jones SE,
    8. Alvarez I,
    9. Bertelli G,
    10. Ortmann O,
    11. Coates AS,
    12. Bajetta E,
    13. Dodwell D,
    14. Coleman RE,
    15. Fallowfield LJ,
    16. Mickiewicz E,
    17. Andersen J,
    18. Lonning PE,
    19. Cocconi G,
    20. Stewart A,
    21. Stuart N,
    22. Snowdon CF,
    23. Carpentieri M,
    24. Massimini G,
    25. Bliss JM,
    26. van de Velde C,
    27. Intergroup Exemestane S
    : A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11): 1081-1092, 2004. PMID: 15014181. DOI: 10.1056/NEJMoa040331
    OpenUrlCrossRefPubMed
    1. Coates AS,
    2. Keshaviah A,
    3. Thurlimann B,
    4. Mouridsen H,
    5. Mauriac L,
    6. Forbes JF,
    7. Paridaens R,
    8. Castiglione-Gertsch M,
    9. Gelber RD,
    10. Colleoni M,
    11. Lang I,
    12. Del Mastro L,
    13. Smith I,
    14. Chirgwin J,
    15. Nogaret JM,
    16. Pienkowski T,
    17. Wardley A,
    18. Jakobsen EH,
    19. Price KN,
    20. Goldhirsch A
    : Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study big 1-98. J Clin Oncol 25(5): 486-492, 2007. PMID: 17200148. DOI: 10.1200/JCO.2006.08.8617
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Cuzick J,
    2. Sestak I,
    3. Baum M,
    4. Buzdar A,
    5. Howell A,
    6. Dowsett M,
    7. Forbes JF
    : Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the atac trial. The Lancet Oncology 11(12): 1135-1141, 2010. DOI: 10.1016/S1470-2045(10)70257-6
    OpenUrlCrossRefPubMed
  10. ↵
    1. Nekhlyudov L,
    2. Li L,
    3. Ross-Degnan D,
    4. Wagner AK
    : Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130(2): 681-689, 2011. PMID: 21842245. DOI: 10.1007/s10549-011-1703-z
    OpenUrlCrossRefPubMed
  11. ↵
    1. Barron TI,
    2. Cahir C,
    3. Sharp L,
    4. Bennett K
    : A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage i-iii breast cancer. Br J Cancer 109(6): 1513-1521, 2013. PMID: 24002590. DOI: 10.1038/bjc.2013.518
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hershman DL,
    2. Shao T,
    3. Kushi LH,
    4. Buono D,
    5. Tsai WY,
    6. Fehrenbacher L,
    7. Kwan M,
    8. Gomez SL,
    9. Neugut AI
    : Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2): 529-537, 2011. PMID: 20803066. DOI: 10.1007/s10549-010-1132-4
    OpenUrlCrossRefPubMed
  13. ↵
    1. Hershman DL,
    2. Kushi LH,
    3. Shao T,
    4. Buono D,
    5. Kershenbaum A,
    6. Tsai WY,
    7. Fehrenbacher L,
    8. Gomez SL,
    9. Miles S,
    10. Neugut AI
    : Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27): 4120-4128, 2010. PMID: 20803066. DOI: 10.1007/s10549-010-1132-4
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Gerber BS,
    2. Cho YI,
    3. Arozullah AM,
    4. Lee SY
    : Racial differences in medication adherence: A cross-sectional study of medicare enrollees. Am J Geriatr Pharmacother 8(2): 136-145, 2010. PMID: 20439063. DOI: 10.1016/j.amjopharm.2010.03.002
    OpenUrlCrossRefPubMed
  15. ↵
    1. Gellad WF,
    2. Haas JS,
    3. Safran DG
    : Race/ethnicity and nonadherence to prescription medications among seniors: Results of a national study. J Gen Intern Med 22(11): 1572-1578, 2007. PMID: 17882499. DOI: 10.1007/s11606-007-0385-z
    OpenUrlCrossRefPubMed
  16. ↵
    1. Morisky DE,
    2. Ang A,
    3. Krousel-Wood M,
    4. Ward HJ
    : Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10(5): 348-354, 2008. PMID: 18453793. DOI: 10.1111/j.1751-7176.2008.07572.x
    OpenUrlCrossRefPubMed
  17. ↵
    1. Morisky DE,
    2. Green LW,
    3. Levine DM
    : Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24(1): 67-74, 1986. PMID: 3945130. DOI: 10.1097/00005650-198601000-00007
    OpenUrlCrossRefPubMed
  18. ↵
    1. Atkins L,
    2. Fallowfield L
    : Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42(14): 2271-2276, 2006. PMID: 16644208. DOI: 10.1016/j.ejca.2006.03.004
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hsieh KP,
    2. Chen LC,
    3. Cheung KL,
    4. Chang CS,
    5. Yang YH
    : Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women--an asian population-based study. PLoS One 9(2): e87027, 2014. PMID: 24586261. DOI: 10.1371/journal.pone.0087027
    OpenUrlCrossRefPubMed
  20. ↵
    1. Ruddy K,
    2. Mayer E,
    3. Partridge A
    : Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1): 56-66, 2009. PMID: 19147869. DOI: 10.3322/caac.20004
    OpenUrlCrossRefPubMed
  21. ↵
    1. Kesmodel SB,
    2. Goloubeva OG,
    3. Rosenblatt PY,
    4. Heiss B,
    5. Bellavance EC,
    6. Chumsri S,
    7. Bao T,
    8. Thompson J,
    9. Nightingale G,
    10. Tait NS,
    11. Nichols EM,
    12. Feigenberg SJ,
    13. Tkaczuk KH
    : Patient-reported adherence to adjuvant aromatase inhibitor therapy using the morisky medication adherence scale: An evaluation of predictors. Am J Clin Oncol 41(5): 508-512, 2018. PMID: 27322700. DOI: 10.1097/COC.0000000000000314
    OpenUrlPubMed
    1. He W,
    2. Fang F,
    3. Varnum C,
    4. Eriksson M,
    5. Hall P,
    6. Czene K
    : Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. J Clin Oncol 33(20): 2262-2269, 2015. PMID: 26033800. DOI: 10.1200/JCO.2014.59.3673
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Wigertz A,
    2. Ahlgren J,
    3. Holmqvist M,
    4. Fornander T,
    5. Adolfsson J,
    6. Lindman H,
    7. Bergkvist L,
    8. Lambe M
    : Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: A population-based study. Breast Cancer Res Treat 133(1): 367-373, 2012. PMID: 22286315. DOI: 10.1007/s10549-012-1961-4
    OpenUrlCrossRefPubMed
  23. ↵
    1. Partridge AH,
    2. LaFountain A,
    3. Mayer E,
    4. Taylor BS,
    5. Winer E,
    6. Asnis-Alibozek A
    : Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4): 556-562, 2008. PMID: 18180462. DOI: 10.1200/JCO.2007.11.5451
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Simon R,
    2. Latreille J,
    3. Matte C,
    4. Desjardins P,
    5. Bergeron E
    : Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg 57(1): 26-32, 2014. PMID: 24461223. DOI: 10.1503/cjs.006211
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Barron TI,
    2. Connolly R,
    3. Bennett K,
    4. Feely J,
    5. Kennedy MJ
    : Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 109(5): 832-839, 2007. PMID: 17243168. DOI: 10.1002/cncr.22485
    OpenUrlCrossRefPubMed
    1. Jankowitz RC,
    2. Davidson NE
    : Adjuvant endocrine therapy for breast cancer: How long is long enough? Oncology (Williston Park) 27(12): 1210-1216, 1224, 2013. PMID: 17243168. DOI: 10.1002/cncr.22485
    OpenUrl
  26. ↵
    1. McCowan C,
    2. Shearer J,
    3. Donnan PT,
    4. Dewar JA,
    5. Crilly M,
    6. Thompson AM,
    7. Fahey TP
    : Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11): 1763-1768, 2008. PMID: 18985046. DOI: 10.1038/sj.bjc.6604758
    OpenUrlCrossRefPubMed
  27. ↵
    1. Baum M,
    2. Budzar AU,
    3. Cuzick J,
    4. Forbes J,
    5. Houghton JH,
    6. Klijn JG,
    7. Sahmoud T,
    8. Group AT
    : Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the atac randomised trial. Lancet 359(9324): 2131-2139, 2002. PMID: 12090977.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Sparano JA,
    2. Gray RJ,
    3. Makower DF,
    4. Pritchard KI,
    5. Albain KS,
    6. Hayes DF,
    7. Geyer CE Jr..,
    8. Dees EC,
    9. Goetz MP,
    10. Olson JA Jr..,
    11. Lively T,
    12. Badve SS,
    13. Saphner TJ,
    14. Wagner LI,
    15. Whelan TJ,
    16. Ellis MJ,
    17. Paik S,
    18. Wood WC,
    19. Ravdin PM,
    20. Keane MM,
    21. Gomez Moreno HL,
    22. Reddy PS,
    23. Goggins TF,
    24. Mayer IA,
    25. Brufsky AM,
    26. Toppmeyer DL,
    27. Kaklamani VG,
    28. Berenberg JL,
    29. Abrams J,
    30. Sledge GW Jr..
    : Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2): 111-121, 2018. PMID: 29860917. DOI: 10.1056/NEJMoa1804710
    OpenUrlPubMed
  29. ↵
    1. Murray MD,
    2. Morrow DG,
    3. Weiner M,
    4. Clark DO,
    5. Tu W,
    6. Deer MM,
    7. Brater DC,
    8. Weinberger M
    : A conceptual framework to study medication adherence in older adults. Am J Geriatr Pharmacother 2(1): 36-43, 2004. PMID: 15555477. DOI: 10.1016/s1543-5946(04)90005-0
    OpenUrlCrossRefPubMed
  30. ↵
    1. Partridge AH,
    2. Wang PS,
    3. Winer EP,
    4. Avorn J
    : Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4): 602-606, 2003. PMID: 12586795. DOI: 10.1200/JCO.2003.07.071
    OpenUrlAbstract/FREE Full Text
    1. Neugut AI,
    2. Zhong X,
    3. Wright JD,
    4. Accordino M,
    5. Yang J,
    6. Hershman DL
    : Nonadherence to medications for chronic conditions and nonadherence to adjuvant hormonal therapy in women with breast cancer. JAMA Oncol 2(10): 1326-1332, 2016. PMID: 27281650. DOI: 10.1001/jamaoncol.2016.1291
    OpenUrlPubMed
  31. ↵
    1. Yang J,
    2. Neugut AI,
    3. Wright JD,
    4. Accordino M,
    5. Hershman DL
    : Nonadherence to oral medications for chronic conditions in breast cancer survivors. J Oncol Pract 12(8): e800-809, 2016. PMID: 27407167. DOI: 10.1200/JOP.2016.011742
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Bright EE,
    2. Petrie KJ,
    3. Partridge AH,
    4. Stanton AL
    : Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Breast Cancer Res Treat 158(2): 243-251, 2016. PMID: 27342455. DOI: 10.1007/s10549-016-3871-3
    OpenUrlPubMed
  33. ↵
    1. Martin LR,
    2. Williams SL,
    3. Haskard KB,
    4. Dimatteo MR
    : The challenge of patient adherence. Ther Clin Risk Manag 1(3): 189-199, 2005. PMID: 18360559.
    OpenUrlPubMed
  34. ↵
    1. Lash TL,
    2. Fox MP,
    3. Westrup JL,
    4. Fink AK,
    5. Silliman RA
    : Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2): 215-220, 2006. PMID: 16541307. DOI: 10.1007/s10549-006-9193-0
    OpenUrlCrossRefPubMed
  35. ↵
    1. Krousel-Wood MA,
    2. Islam T,
    3. Webber LS,
    4. Re RS,
    5. Morisky DE,
    6. Muntner P
    : New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 15(1): 59-66, 2009. PMID: 19146365.
  36. ↵
    1. Morisky DE,
    2. DiMatteo MR
    : Improving the measurement of self-reported medication nonadherence: Final response. J Clin Epidemiol 64(3): 258-263, 2011. PMID: 21144706. DOI: 10.1016/j.jclinepi.2010.09.002
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (2)
Anticancer Research
Vol. 40, Issue 2
February 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
16 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer
ALEXANDER PHILIPOVSKIY, ALELI CAMPBELL, ROSALINDA HEYDARIAN, BRENDA CASTILLO, ALOK K. DWIVEDI, RICHARD MCCALLUM, RENATO AGUILERA, SUMIT GAUR, ZEINA NAHLEH
Anticancer Research Feb 2020, 40 (2) 857-864; DOI: 10.21873/anticanres.14018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer
ALEXANDER PHILIPOVSKIY, ALELI CAMPBELL, ROSALINDA HEYDARIAN, BRENDA CASTILLO, ALOK K. DWIVEDI, RICHARD MCCALLUM, RENATO AGUILERA, SUMIT GAUR, ZEINA NAHLEH
Anticancer Research Feb 2020, 40 (2) 857-864; DOI: 10.21873/anticanres.14018
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
Show more Clinical Studies

Similar Articles

Keywords

  • Adjuvant aromatase inhibitor
  • breast cancer
  • postmenopausal
  • adherence
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire